Mayne Pharma Group Limited operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Mayne Pharma Group Limited with three other
pharmaceutical manufacturers in Australasia:
sales of 75.72 million Australian Dollars [US$53.93 million]
(3.43 million Australian Dollars [US$2.44 million]
of which 100%
was Pharmaceutical Research and Development), and
AFT Pharmaceuticals Ltd
based in New Zealand
(80.07 million New Zealand Dollars [US$54.96 million]
of which 61%
During the year ended June of 2018, sales at
Mayne Pharma Group Limited were A$530.31 million (US$377.72 million).
decrease of 7.4%
versus 2017, when the company's sales were A$572.60 million.
Contributing to the drop in overall sales was the 27.8% decline
in Specialty Brands, from A$61.86 million to A$44.68 million.
There were also decreases in sales in
Generic Products (down 7.9% to A$385.70 million)
However, these declines were partially offset by the increase in sales of
Metrics Contract Services (Mcs) (up 9.1% to A$63.08 million)
Mayne Pharma International (Mpi) (up 7.5% to A$36.84 million)